Previous 10 | Next 10 |
Invitae Launches Enhanced Chemistry of MRD Test to Better Serve Biopharmaceutical Clinical and Research Partnerships PR Newswire – Helps to detect circulating tumor DNA (ctDNA) as a biomarker in clinical research and clinical trials for solid tumor malignancies –...
2023-11-04 09:59:00 ET Genetic-testing company, Invitae (NYSE: NVTA) , isn't as easy to understand as it might seem. After more than a year of pivoting and scaling down its operations, changing its leadership, and renegotiating some of its debt, there's been a lot of activity which ...
Invitae to Announce Third Quarter 2023 Financial Results on Wednesday, November 8, 2023 PR Newswire SAN FRANCISCO , Nov. 1, 2023 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced that it will report its third q...
Landmark Study Reveals Magnitude of Uncertain Results in Clinical Genetic Testing for Hereditary Disease, Points to Evidence-Based Solutions to Reach Definitive Results PR Newswire – Findings set to enhance patient care and reduce uncertainty in test results as clinicians...
2023-10-19 16:36:27 ET More on Invitae Invitae: Revenue Troubles Build Biggest stock movers today: Arch Resources, Coinbase Global and more Invitae jumps as FDA clears first-of-its-kind cancer test For further details see: Invitae appoints David Sholehvar...
Invitae Appoints Dr. David Sholehvar as Chief Operating Officer PR Newswire SAN FRANCISCO , Oct. 19, 2023 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced the appointment of veteran healthcare leader David Sholeh...
Rural Hospital System Demonstrates the Clinical Benefits of Implementing Universal Hereditary Cancer Testing in Patients with Breast Cancer PR Newswire – Invitae retrospective analysis reinforces the clinical actionability of following the ASBrS guidelines – ...
Invitae to Present Data at the National Society of Genetic Counselors 42nd Annual Conference That Supports Advancements in Medical Genomics PR Newswire - Sponsor of the Heart of Genetic Counseling program and award, recognizing excellence in patient care - - These studies co...
Invitae's Common Hereditary Cancers Panel Receives FDA Market Authorization PR Newswire – First-of-its-kind authorization provides potential marketing differentiation and opportunities for largest testing category – – Testament to Invitae's product and l...
2023-10-02 16:20:56 ET Shares of Invitae (NYSE: NVTA) roared as much as 37% higher early Monday, then settled to trade up 13% as of 3 p.m. ET after the U.S Food and Drug Administration (FDA) authorized marketing efforts by Invitae for its groundbreaking gene-based test for cancer ri...
News, Short Squeeze, Breakout and More Instantly...
Thursday, Labcorp (NYSE:LH) reported first-quarter sales increased 4.6% to $3.18 billion, beating the consensus of $3.12 billion. Base Bu...
Labcorp Announces Winning Bid for Select Assets of Invitae PR Newswire Advances Labcorp strategy to launch and scale specialty testing in areas such as oncology and rare diseases Transaction requires court approval, with confirmation expected on May 6, 2024 ...
Invitae Enters into Agreement with Labcorp for Sale of Business PR Newswire – Labcorp Selected as Winning Bidder in Court-Supervised Sale Process, Subject to Court and Regulatory Approvals – – $239 Million Cash Bid Includes Acquisition of Substantial...